Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence

Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence

Already used for the treatment of some allergic and inflammatory diseases, such as asthma or atopic dermatitis, dupilumab has also been approved as add-on therapy for patients with CRSwNP, and it could represent the keystone to reducing the remission time as well as to improve healing and quality of...

Full description

Bibliographic Details
Main Authors: Selena Mimmi, Nicola Lombardo, Domenico Maisano, Giovanna Piazzetta, Corrado Pelaia, Girolamo Pelaia, Marta Greco, Daniela Foti, Vincenzo Dattilo, Enrico Iaccino
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Genes
Subjects:
miRNAs
antibody therapeutics
anti-IL-4/IL-13 receptor
dupilumab
nasal polyposis
interleukins
Online Access:https://www.mdpi.com/2073-4425/13/12/2366

Internet

https://www.mdpi.com/2073-4425/13/12/2366

Similar Items